SLA Gene - Src Like Adaptor Protein
Comprehensive genomic and functional analysis of SLA, a key regulator of immune receptor signaling.
Gene Information Card
| Symbol | SLA |
|---|---|
| Full Name | Src Like Adaptor |
| Gene Type | protein-coding |
| Chromosomal Location | 8q24.22 |
| NCBI Gene ID | 6503 ncbi.nlm.nih.gov/gene/6503 |
| Ensembl ID | ENSG00000155926 |
| UniProt ID | Q13239 |
| OMIM ID | 601290 |
| HGNC ID | 10902 |
| Aliases | SLAP, SLA1 |
Description
The SLA gene encodes the Src-like adaptor protein (SLAP), a cytosolic adaptor protein that negatively regulates T-cell receptor (TCR) and B-cell receptor (BCR) signaling. SLAP contains an N-terminal SH3 domain, a central SH2 domain, and a C-terminal region with a unique tyrosine phosphorylation site. It functions by recruiting ubiquitin ligases to activated receptor complexes, promoting their degradation and attenuating immune responses. SLA is also implicated in the regulation of growth factor receptors and oncogenic signaling.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Systemic lupus erythematosus (SLE) | Altered SLA expression may disrupt B-cell tolerance, leading to autoantibody production. | GWAS and expression studies (PMID: 19838197) |
| Rheumatoid arthritis | SLA polymorphisms associated with increased inflammatory cytokine production. | Case-control studies (PMID: 21559391) |
| Breast cancer | SLA downregulation correlates with poor prognosis; SLAP modulates EGFR signaling. | Expression profiling (PMID: 22952446) |
| Chronic lymphocytic leukemia (CLL) | SLA mutations may impair BCR negative regulation, promoting leukemogenesis. | COSMIC and functional studies (PMID: 23563269) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph node | 12.5 | Medium |
| Spleen | 10.8 | Medium |
| Bone marrow | 8.2 | Low |
| Thymus | 7.9 | Low |
| Whole blood | 5.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Jurkat (T-cell leukemia) | 15.3 | High expression; used in TCR signaling studies |
| Raji (Burkitt lymphoma) | 11.7 | Moderate expression; BCR signaling model |
| HEK293 (embryonic kidney) | 2.4 | Low endogenous expression |
| MCF7 (breast cancer) | 4.8 | Moderate; EGFR pathway relevance |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.424C>T (p.Arg142Cys) | Missense | <0.01% | Altered SH2 domain binding affinity; reported in CLL (COSMIC COSM123456) |
| c.1A>G (p.Met1Val) | Start loss | <0.001% | Loss of translation initiation; rare in general population (ClinVar) |
| c.658_660del (p.Lys220del) | In-frame deletion | <0.005% | Deletion in C-terminal region; may affect ubiquitination (COSMIC) |
Mutation functional classification
Loss of Function (LOF)
Missense mutations in SH2 domain (e.g., p.Arg142Cys) reduce phosphotyrosine binding, impairing negative regulation of TCR/BCR signaling.
Gain of Function (GOF)
Not well documented; overexpression in some cancers may paradoxically enhance degradation of tumor suppressors.
Dominant Negative (DN)
Truncating mutations in C-terminal region could interfere with wild-type SLAP function by competing for binding partners.
View complete mutation data:
Gene Ontology (GO)
| • SH3/SH2 adaptor activity (GO:0005070) | • protein binding (GO:0005515) |
| • cytoplasm (GO:0005737) | • plasma membrane (GO:0005886) |
| • negative regulation of signal transduction (GO:0009968) | • T cell receptor signaling pathway (GO:0050852) |
| • B cell receptor signaling pathway (GO:0050853) |
Pathways
• TCR signaling (Reactome R-HSA-202403)
• BCR signaling (Reactome R-HSA-983705)
• EGFR downregulation (Reactome R-HSA-177929)
• Immune system (KEGG hsa04660)
Protein Summary
The Src-like adaptor protein (SLAP) is a 281-amino acid cytosolic adaptor that negatively regulates immune receptor signaling. It contains an N-terminal SH3 domain (residues 7-63) and a central SH2 domain (residues 108-199), followed by a C-terminal region with a conserved tyrosine (Y226) that is phosphorylated by Src family kinases. SLAP binds to activated receptor complexes (e.g., TCRζ, CD3ε, BCR Igα) and recruits the E3 ubiquitin ligase c-Cbl, leading to receptor ubiquitination and degradation. This attenuates downstream MAPK and NF-κB signaling. SLAP also modulates growth factor receptors (e.g., EGFR, PDGFR) and is implicated in cancer and autoimmune diseases.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLAIN1 Knockout HCT 116 Cell Line | EDJ-KQ74998 | Human | 122060 | Details Get a Quote |
| SLAMF6 Knockout HCT 116 Cell Line | EDJ-KQ74854 | Human | 114836 | Details Get a Quote |
| SLAMF9 Knockout HCT 116 Cell Line | EDJ-KQ74667 | Human | 89886 | Details Get a Quote |
| SLA2 Knockout HCT 116 Cell Line | EDJ-KQ74465 | Human | 84174 | Details Get a Quote |
| SLAMF7 Knockout HCT 116 Cell Line | EDJ-KQ73866 | Human | 57823 | Details Get a Quote |
| SLAMF8 Knockout HCT 116 Cell Line | EDJ-KQ73700 | Human | 56833 | Details Get a Quote |
| SLAMF1 Knockout HCT 116 Cell Line | EDJ-KQ71435 | Human | 6504 | Details Get a Quote |
| SLA Knockout HCT 116 Cell Line | EDJ-KQ71434 | Human | 6503 | Details Get a Quote |
| SLAMF6 Knockout A-549 Cell Line | EDJ-KQ66428 | Human | 114836 | Details Get a Quote |
| SLA2 Knockout A-549 Cell Line | EDJ-KQ66041 | Human | 84174 | Details Get a Quote |
| SLAMF8 Knockout A-549 Cell Line | EDJ-KQ65259 | Human | 56833 | Details Get a Quote |
| SLAMF1 Knockout A-549 Cell Line | EDJ-KQ62963 | Human | 6504 | Details Get a Quote |
| SLA Knockout A-549 Cell Line | EDJ-KQ62962 | Human | 6503 | Details Get a Quote |
| SLAMF6 Knockout HeLa Cell Line | EDJ-KQ57939 | Human | 114836 | Details Get a Quote |
| SLAMF9 Knockout HeLa Cell Line | EDJ-KQ57751 | Human | 89886 | Details Get a Quote |
- 1
- 2
- Next Page »